Simvastatin and Niacin, Antioxidant Vitamins, or the Combination for the Prevention of Coronary Disease
B. Greg Brown, M.D., Ph.D., Xue-Qiao Zhao, M.D., Alan Chait, M.D., Lloyd D. Fisher, Ph.D., Marian C. Cheung, Ph.D., Josh S. Morse, B.S., Alice A. Dowdy, R.D., Emily K. Marino, M.S., Edward L. Bolson, M.S., Petar Alaupovic, Ph.D., Jiri Frohlich, M.D., Leny Serafini, B.S., Ellen Huss-Frechette, B.S., Shari Wang, B.S., Debbie DeAngelis, R.T., Arthur Dodek, M.D., and John J. Albers, Ph.D.
Background Both lipid-modifying therapy and antioxidant vitaminsare thought to have benefit in patients with coronary disease.We studied simvastatin–niacin and antioxidant-vitamintherapy, alone and together, for cardiovascular protection inpatients with coronary disease and low plasma levels of high-densitylipoprotein (HDL) cholesterol.
Methods In a three-year, double-blind trial, 160 patients withcoronary disease, low HDL cholesterol levels, and normal low-densitylipoprotein (LDL) cholesterol levels were randomly assignedto receive one of four regimens: simvastatin plus niacin, antioxidants,simvastatin–niacin plus antioxidants, or placebos. Theend points were arteriographic evidence of a change in coronarystenosis and the occurrence of a first cardiovascular event(death, myocardial infarction, stroke, or revascularization).
Results The mean levels of LDL and HDL cholesterol were unalteredin the antioxidant group and the placebo group; these levelschanged substantially (by –42 percent and +26 percent,respectively) in the simvastatin–niacin group. The protectiveincrease in HDL2 with simvastatin plus niacin was attenuatedby concurrent therapy with antioxidants. The average stenosisprogressed by 3.9 percent with placebos, 1.8 percent with antioxidants(P=0.16 for the comparison with the placebo group), and 0.7percent with simvastatin–niacin plus antioxidants (P=0.004)and regressed by 0.4 percent with simvastatin–niacin alone(P<0.001). The frequency of the clinical end point was 24percent with placebos, 3 percent with simvastatin–niacinalone, 21 percent in the antioxidant-therapy group, and 14 percentin the group given simvastatin–niacin plus antioxidants.
Conclusions Simvastatin plus niacin provides marked clinicaland angiographically measurable benefits in patients with coronarydisease and low HDL levels. The use of antioxidant vitaminsin this setting must be questioned.
Source Information
From the Department of Medicine, Division of Cardiology (B.G.B., X.-Q.Z., J.S.M., E.L.B.), the Division of Metabolism, Endocrinology, and Nutrition (A.C., M.C.C., A.A.D., J.J.A.), and the Department of Biostatistics (L.D.F., E.K.M.), University of Washington School of Medicine, Seattle; the Oklahoma Medical Research Foundation, Oklahoma City (P.A.); and the Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada (J.F.).
Other authors were Leny Serafini, B.S., Ellen Huss-Frechette, B.S., and Shari Wang, B.S. (Department of Medicine, University of Washington School of Medicine, Seattle); and Debbie DeAngelis, R.T., and Arthur Dodek, M.D. (Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada).
Address reprint requests to Dr. Brown at the Division of Cardiology, Box 356422, Health Sciences Bldg., Rm. A509, University of Washington, 1959 N.E. Pacific St., Seattle, WA 98195.
What Vitamins Should I Be Taking?
Blackman B. T., Opie L. H., Tulchinsky T.H., Nizan-Kaluski D., Willett W. C., Stampfer M. J.
Extract |
Full Text |
PDF
N Engl J Med 2002;
346:1914-1916, Jun 13, 2002.
Correspondence
This article has been cited by other articles:
The Emerging Risk Factors Collaboration,
(2009). Major Lipids, Apolipoproteins, and Risk of Vascular Disease. JAMA
302: 1993-2000
[Abstract][Full Text]
Lee, J. M.S., Robson, M. D., Yu, L.-M., Shirodaria, C. C., Cunnington, C., Kylintireas, I., Digby, J. E., Bannister, T., Handa, A., Wiesmann, F., Durrington, P. N., Channon, K. M., Neubauer, S., Choudhury, R. P.
(2009). Effects of high-dose modified-release nicotinic Acid on atherosclerosis and vascular function a randomized, placebo-controlled, magnetic resonance imaging study.. J Am Coll Cardiol
54: 1787-1794
[Abstract][Full Text]
Jaffer, F. A.
(2009). Assessing niacin as an atherosclerosis therapeutic agent valuable insights provided by high-resolution vascular magnetic resonance imaging.. J Am Coll Cardiol
54: 1795-1796
[Full Text]
Bitzur, R., Cohen, H., Kamari, Y., Shaish, A., Harats, D.
(2009). Triglycerides and HDL Cholesterol: Stars or second leads in diabetes?. Diabetes Care
32: S373-S377
[Full Text]
Grover, S. A., Kaouache, M., Joseph, L., Barter, P., Davignon, J.
(2009). Evaluating the Incremental Benefits of Raising High-Density Lipoprotein Cholesterol Levels During Lipid Therapy After Adjustment for the Reductions in Other Blood Lipid Levels. Arch Intern Med
169: 1775-1780
[Abstract][Full Text]
Whayne, T. F. Jr
(2009). High-density Lipoprotein Cholesterol: Current Perspective for Clinicians. ANGIOLOGY
60: 644-649
[Abstract]
Su, Z., Ishimori, N., Chen, Y., Leiter, E. H., Churchill, G. A., Paigen, B., Stylianou, I. M.
(2009). Four additional mouse crosses improve the lipid QTL landscape and identify Lipg as a QTL gene. J. Lipid Res.
50: 2083-2094
[Abstract][Full Text]
Bloomgarden, Z. T.
(2009). The 6th Annual World Congress on the Insulin Resistance Syndrome. Diabetes Care
32: e114-e121
[Full Text]
Miller, M.
(2009). Dyslipidemia and cardiovascular risk: the importance of early prevention. QJM
102: 657-667
[Abstract][Full Text]
Tardif, J.-C.
(2009). Angiotensin-converting enzyme inhibitors and atherosclerotic plaque: a key role in the cardiovascular protection of patients with coronary artery disease. Eur Heart J Suppl
11: E9-E16
[Abstract][Full Text]
Laclaustra, M., Navas-Acien, A., Stranges, S., Ordovas, J. M., Guallar, E.
(2009). Serum Selenium Concentrations and Hypertension in the US Population. Circ Cardiovasc Qual Outcomes
2: 369-376
[Abstract][Full Text]
Superko, H. R.
(2009). Advanced Lipoprotein Testing and Subfractionation Are Clinically Useful. Circulation
119: 2383-2395
[Full Text]
Bleys, J., Navas-Acien, A., Laclaustra, M., Pastor-Barriuso, R., Menke, A., Ordovas, J., Stranges, S., Guallar, E.
(2009). Serum Selenium and Peripheral Arterial Disease: Results From the National Health and Nutrition Examination Survey, 2003-2004. Am J Epidemiol
169: 996-1003
[Abstract][Full Text]
Goldenberg, I., Boyko, V., Tennenbaum, A., Tanne, D., Behar, S., Guetta, V.
(2009). Long-term Benefit of High-Density Lipoprotein Cholesterol-Raising Therapy With Bezafibrate: 16-Year Mortality Follow-up of the Bezafibrate Infarction Prevention Trial. Arch Intern Med
169: 508-514
[Abstract][Full Text]
Kim, E. S.H., Menon, V.
(2009). Status of Women in Cardiovascular Clinical Trials. Arterioscler. Thromb. Vasc. Bio.
29: 279-283
[Full Text]
Briel, M., Ferreira-Gonzalez, I., You, J. J, Karanicolas, P. J, Akl, E. A, Wu, P., Blechacz, B., Bassler, D., Wei, X., Sharman, A., Whitt, I., Alves da Silva, S., Khalid, Z., Nordmann, A. J, Zhou, Q., Walter, S. D, Vale, N., Bhatnagar, N., O'Regan, C., Mills, E. J, Bucher, H. C, Montori, V. M, Guyatt, G. H
(2009). Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ
338: b92-b92
[Abstract][Full Text]
Goumas, G. S.
(2009). Is There Evidence-based Hypolipidemic Treatment With Clinical Benefit Beyond Statins?. ANGIOLOGY
60: 93-98
[Abstract]
Robinson, J. G., Wang, S., Smith, B. J., Jacobson, T. A.
(2009). Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk.. J Am Coll Cardiol
53: 316-322
[Abstract][Full Text]
Yates, A., Norwig, J., Maroon, J. C., Bost, J., Bradley, J. P., Duca, M., Wecht, D. A., Grove, R., Iso, A., Cobb, I., Ross, N., Borden, M.
(2009). Evaluation of Lipid Profiles and the Use of Omega-3 Essential Fatty Acid in Professional Football Players. Sports Health: A Multidisciplinary Approach
1: 21-30
[Abstract][Full Text]
Onufrak, S. J., Bellasi, A., Cardarelli, F., Vaccarino, V., Muntner, P., Shaw, L. J., Raggi, P.
(2009). Investigation of Gender Heterogeneity in the Associations of Serum Phosphorus With Incident Coronary Artery Disease and All-Cause Mortality. Am J Epidemiol
169: 67-77
[Abstract][Full Text]
Nicholls, S. J., Tuzcu, E. M., Brennan, D. M., Tardif, J.-C., Nissen, S. E.
(2008). Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis: Insights From ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation
118: 2506-2514
[Abstract][Full Text]
Papaliodis, D., Boucher, W., Kempuraj, D., Michaelian, M., Wolfberg, A., House, M., Theoharides, T. C.
(2008). Niacin-induced "Flush" Involves Release of Prostaglandin D2 from Mast Cells and Serotonin from Platelets: Evidence from Human Cells in Vitro and an Animal Model. J. Pharmacol. Exp. Ther.
327: 665-672
[Abstract][Full Text]
Sesso, H. D., Buring, J. E., Christen, W. G., Kurth, T., Belanger, C., MacFadyen, J., Bubes, V., Manson, J. E., Glynn, R. J., Gaziano, J. M.
(2008). Vitamins E and C in the Prevention of Cardiovascular Disease in Men: The Physicians' Health Study II Randomized Controlled Trial. JAMA
300: 2123-2133
[Abstract][Full Text]
Fruchart, J.-C., Sacks, F. M, Hermans, M. P, Assmann, G., Brown, W V., Ceska, R., Chapman, M J., Dodson, P. M, Fioretto, P., Ginsberg, H. N, Kadowaki, T., Lablanche, J.-M., Marx, N., Plutzky, J., Reiner, Z., Rosenson, R. S, Staels, B., Stock, J. K, Sy, R., Wanner, C., Zambon, A., Zimmet, P.
(2008). The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. Diabetes and Vascular Disease Research
5: 319-335
[Abstract]
van der Hoorn, J. W.A., de Haan, W., Berbee, J. F.P., Havekes, L. M., Jukema, J. W., Rensen, P. C.N., Princen, H. M.G.
(2008). Niacin Increases HDL by Reducing Hepatic Expression and Plasma Levels of Cholesteryl Ester Transfer Protein in APOE*3Leiden.CETP Mice. Arterioscler. Thromb. Vasc. Bio.
28: 2016-2022
[Abstract][Full Text]
Hausenloy, D J, Yellon, D M
(2008). Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Postgrad. Med. J.
84: 590-598
[Abstract][Full Text]
Green, P. S., Vaisar, T., Pennathur, S., Kulstad, J. J., Moore, A. B., Marcovina, S., Brunzell, J., Knopp, R. H., Zhao, X.-Q., Heinecke, J. W.
(2008). Combined Statin and Niacin Therapy Remodels the High-Density Lipoprotein Proteome. Circulation
118: 1259-1267
[Abstract][Full Text]
Lamon-Fava, S., Diffenderfer, M. R., Barrett, P. H. R., Buchsbaum, A., Nyaku, M., Horvath, K. V., Asztalos, B. F., Otokozawa, S., Ai, M., Matthan, N. R., Lichtenstein, A. H., Dolnikowski, G. G., Schaefer, E. J.
(2008). Extended-Release Niacin Alters the Metabolism of Plasma Apolipoprotein (Apo) A-I and ApoB-Containing Lipoproteins. Arterioscler. Thromb. Vasc. Bio.
28: 1672-1678
[Abstract][Full Text]
Blaha, M. J., Bansal, S., Rouf, R., Golden, S. H., Blumenthal, R. S., DeFilippis, A. P.
(2008). A Practical 'ABCDE' Approach to the Metabolic Syndrome. Mayo Clin Proc.
83: 932-943
[Abstract][Full Text]
Nissen, S. E., Nicholls, S. J., Wolski, K.
(2008). Rimonabant and Progression of Atherosclerosis in Obese Persons--Reply. JAMA
300: 280-281
[Full Text]
Choi, S. H., Chae, A., Miller, E., Messig, M., Ntanios, F., DeMaria, A. N., Nissen, S. E., Witztum, J. L., Tsimikas, S.
(2008). Relationship Between Biomarkers of Oxidized Low-Density Lipoprotein, Statin Therapy, Quantitative Coronary Angiography, and Atheroma Volume Observations From the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) Study.. J Am Coll Cardiol
52: 24-32
[Abstract][Full Text]
deGoma, E. M., deGoma, R. L., Rader, D. J.
(2008). Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches.. J Am Coll Cardiol
51: 2199-2211
[Abstract][Full Text]
Bloomgarden, Z. T.
(2008). Cardiovascular Disease in Diabetes. Diabetes Care
31: 1260-1266
[Full Text]
Wild, S., Byrne, C. D
(2008). Time to rethink high-density lipoprotein?. Heart
94: 692-694
[Full Text]
Hausenloy, D J, Yellon, D M
(2008). Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Heart
94: 706-714
[Abstract][Full Text]
Movva, R., Rader, D. J.
(2008). Laboratory Assessment of HDL Heterogeneity and Function. Clin. Chem.
54: 788-800
[Abstract][Full Text]
Guyton, J. R., Brown, B. G., Fazio, S., Polis, A., Tomassini, J. E., Tershakovec, A. M.
(2008). Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.. J Am Coll Cardiol
51: 1564-1572
[Abstract][Full Text]
Brunzell, J. D., Davidson, M., Furberg, C. D., Goldberg, R. B., Howard, B. V., Stein, J. H., Witztum, J. L.
(2008). Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus Conference Report From the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol
51: 1512-1524
[Full Text]
Brown, B. G., Taylor, A. J.
(2008). Does ENHANCE Diminish Confidence in Lowering LDL or in Ezetimibe?. NEJM
358: 1504-1507
[Full Text]
Kastelein, J. J.P., de Groot, E.
(2008). Ultrasound imaging techniques for the evaluation of cardiovascular therapies. Eur Heart J
29: 849-858
[Abstract][Full Text]
Brunzell, J. D., Davidson, M., Furberg, C. D., Goldberg, R. B., Howard, B. V., Stein, J. H., Witztum, J. L.
(2008). Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care
31: 811-822
[Full Text]
Goldberg, R. B., Jacobson, T. A.
(2008). Effects of Niacin on Glucose Control in Patients With Dyslipidemia. Mayo Clin Proc.
83: 470-478
[Abstract][Full Text]
Zhao, X.-Q., Brown, B. G.
(2008). ApoA-I(Milano)/phospholipid complex: clinical implications of dose-response studies in rabbit atherosclerosis with intravascular ultrasound and magnetic resonance imaging.. J Am Coll Cardiol
51: 1110-1111
[Full Text]
Ferns, G., Keti, V.
(2008). HDL-cholesterol modulation and its impact on the management of cardiovascular risk. Ann Clin Biochem
45: 122-128
[Abstract][Full Text]
Blum, S., Milman, U., Shapira, C., Miller-Lotan, R., Bennett, L., Kostenko, M., Landau, M., Keidar, S., Levy, Y., Khemlin, A., Radan, A., Levy, A. P.
(2008). Dual Therapy With Statins and Antioxidants Is Superior to Statins Alone in Decreasing the Risk of Cardiovascular Disease in a Subgroup of Middle-Aged Individuals With Both Diabetes Mellitus and the Haptoglobin 2-2 Genotype. Arterioscler. Thromb. Vasc. Bio.
28: e18-e20
[Full Text]
Josan, K. MD, Majumdar, S. R. MD MPH, McAlister, F. A. MD MSc
(2008). The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ
178: 576-584
[Abstract][Full Text]
Superko, H. R., King, S. III
(2008). Lipid Management to Reduce Cardiovascular Risk: A New Strategy Is Required. Circulation
117: 560-568
[Full Text]
deGoma, E. M., Leeper, N. J., Heidenreich, P. A.
(2008). Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol.. J Am Coll Cardiol
51: 49-55
[Abstract][Full Text]
Lavie, C. J., Milani, R. V.
(2008). Shedding light on high-density lipoprotein cholesterol: the post-ILLUMINATE era.. J Am Coll Cardiol
51: 56-58
[Full Text]
Siekmeier, R., Steffen, C., Marz, W.
(2007). Role of Oxidants and Antioxidants in Atherosclerosis: Results of In Vitro and In Vivo Investigations. J CARDIOVASC PHARMACOL THER
12: 265-282
[Abstract]
Leonard, S. W., Joss, J. D., Mustacich, D. J., Blatt, D. H., Lee, Y. S., Traber, M. G.
(2007). Effects of vitamin E on cholesterol levels of hypercholesterolemic patients receiving statins. Am J Health Syst Pharm
64: 2257-2266
[Abstract][Full Text]
Deeg, M. A., Buse, J. B., Goldberg, R. B., Kendall, D. M., Zagar, A. J., Jacober, S. J., Khan, M. A., Perez, A. T., Tan, M. H., on behalf of the GLAI Study Investigators,
(2007). Pioglitazone and Rosiglitazone Have Different Effects on Serum Lipoprotein Particle Concentrations and Sizes in Patients With Type 2 Diabetes and Dyslipidemia. Diabetes Care
30: 2458-2464
[Abstract][Full Text]
Criqui, M. H.
(2007). Triglycerides and Coronary Heart Disease Revisited (Again). ANN INTERN MED
147: 425-427
[Full Text]
Brunzell, J. D.
(2007). Hypertriglyceridemia. NEJM
357: 1009-1017
[Full Text]
Rainwater, D. L, Mahaney, M. C, VandeBerg, J. L, Wang, X. L.
(2007). Vitamin E dietary supplementation significantly affects multiple risk factors for cardiovascular disease in baboons. Am. J. Clin. Nutr.
86: 597-603
[Abstract][Full Text]
Wieser, F., Cohen, M., Gaeddert, A., Yu, J., Burks-Wicks, C., Berga, S. L., Taylor, R. N.
(2007). Evolution of medical treatment for endometriosis: back to the roots?. Hum Reprod Update
13: 487-499
[Abstract][Full Text]
Singh, I. M., Shishehbor, M. H., Ansell, B. J.
(2007). High-Density Lipoprotein as a Therapeutic Target: A Systematic Review. JAMA
298: 786-798
[Abstract][Full Text]
Cook, N. R., Albert, C. M., Gaziano, J. M., Zaharris, E., MacFadyen, J., Danielson, E., Buring, J. E., Manson, J. E.
(2007). A Randomized Factorial Trial of Vitamins C and E and Beta Carotene in the Secondary Prevention of Cardiovascular Events in Women: Results From the Women's Antioxidant Cardiovascular Study. Arch Intern Med
167: 1610-1618
[Abstract][Full Text]
Yu, C.-M., Zhang, Q., Lam, L., Lin, H., Kong, S.-L., Chan, W., Fung, J. W.-H., Cheng, K. K K, Chan, I. H.-S., Lee, S. W.-L., Sanderson, J. E, Lam, C. W.-K.
(2007). Comparison of intensive and low-dose atorvastatin therapy in the reduction of carotid intimal-medial thickness in patients with coronary heart disease. Heart
93: 933-939
[Abstract][Full Text]
McBride, P. E.
(2007). Triglycerides and Risk for Coronary Heart Disease. JAMA
298: 336-338
[Full Text]
Raggi, P., Bellasi, A.
(2007). Review: Imaging to assess effect of medical therapy in patients with diabetes mellitus. British Journal of Diabetes & Vascular Disease
7: 157-164
[Abstract]
Nogueira, J., Weir, M.
(2007). The Unique Character of Cardiovascular Disease in Chronic Kidney Disease and Its Implications for Treatment with Lipid-Lowering Drugs. CJASN
2: 766-785
[Abstract][Full Text]
Rosenbaum, C. C.
(2007). The History of Complementary and Alternative Medicine in the US. The Annals of Pharmacotherapy
41: 1256-1260
[Full Text]
Windler, E., Schoffauer, M., Zyriax, B.-C.
(2007). The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease. Diabetes and Vascular Disease Research
4: 136-142
[Abstract]
Garg, A., Simha, V.
(2007). Update on Dyslipidemia. J. Clin. Endocrinol. Metab.
92: 1581-1589
[Abstract][Full Text]
Bleys, J., Miller, E. R III, Appel, L. J, Guallar, E.
(2007). Reply to J Hathcock. Am. J. Clin. Nutr.
85: 1435-1436
[Full Text]
Davidson, M. H., Robinson, J. G.
(2007). Safety of Aggressive Lipid Management. J Am Coll Cardiol
49: 1753-1762
[Abstract][Full Text]
Lee, J. M S, Choudhury, R. P
(2007). Prospects for atherosclerosis regression through increase in high-density lipoprotein and other emerging therapeutic targets. Heart
93: 559-564
[Abstract][Full Text]
Berry, C., L'Allier, P. L., Gregoire, J., Lesperance, J., Levesque, S., Ibrahim, R., Tardif, J.-C.
(2007). Comparison of Intravascular Ultrasound and Quantitative Coronary Angiography for the Assessment of Coronary Artery Disease Progression. Circulation
115: 1851-1857
[Abstract][Full Text]
Kwan, B. C.H., Kronenberg, F., Beddhu, S., Cheung, A. K.
(2007). Lipoprotein Metabolism and Lipid Management in Chronic Kidney Disease. J. Am. Soc. Nephrol.
18: 1246-1261
[Full Text]
Nissen, S. E., Tardif, J.-C., Nicholls, S. J., Revkin, J. H., Shear, C. L., Duggan, W. T., Ruzyllo, W., Bachinsky, W. B., Lasala, G. P., Tuzcu, E. M., the ILLUSTRATE Investigators,
(2007). Effect of Torcetrapib on the Progression of Coronary Atherosclerosis. NEJM
356: 1304-1316
[Abstract][Full Text]
Brown, B. G., Zhao, X.-Q.
(2007). Is Intravascular Ultrasound the Gold Standard Surrogate for Clinically Relevant Atherosclerosis Progression?. J Am Coll Cardiol
49: 933-938
[Abstract][Full Text]
Bose, D., von Birgelen, C., Erbel, R.
(2007). Intravascular Ultrasound for the Evaluation of Therapies Targeting Coronary Atherosclerosis. J Am Coll Cardiol
49: 925-932
[Abstract][Full Text]
Singh, U., Otvos, J., Dasgupta, A., de Lemos, J. A., Devaraj, S., Jialal, I.
(2007). High-Dose {alpha}-Tocopherol Therapy Does Not Affect HDL Subfractions in Patients with Coronary Artery Disease on Statin Therapy. Clin. Chem.
53: 525-528
[Abstract][Full Text]
Sanossian, N., Saver, J. L., Navab, M., Ovbiagele, B.
(2007). High-Density Lipoprotein Cholesterol: An Emerging Target for Stroke Treatment. Stroke
38: 1104-1109
[Abstract][Full Text]
Bjelakovic, G., Nikolova, D., Gluud, L. L., Simonetti, R. G., Gluud, C.
(2007). Mortality in Randomized Trials of Antioxidant Supplements for Primary and Secondary Prevention: Systematic Review and Meta-analysis. JAMA
297: 842-857
[Abstract][Full Text]
Nicholls, S. J., Tuzcu, E. M., Sipahi, I., Grasso, A. W., Schoenhagen, P., Hu, T., Wolski, K., Crowe, T., Desai, M. Y., Hazen, S. L., Kapadia, S. R., Nissen, S. E.
(2007). Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis. JAMA
297: 499-508
[Abstract][Full Text]
Hilpert, K. F, West, S. G, Kris-Etherton, P. M, Hecker, K. D, Simpson, N. M, Alaupovic, P.
(2007). Postprandial effect of n-3 polyunsaturated fatty acids on apolipoprotein B-containing lipoproteins and vascular reactivity in type 2 diabetes. Am. J. Clin. Nutr.
85: 369-376
[Abstract][Full Text]
Reasner, C.
(2007). Rational therapy of mixed dyslipidaemia in a patient with diabetes. British Journal of Diabetes & Vascular Disease
7: 25-30
[Abstract]
Traber, M. G
(2007). Heart disease and single-vitamin supplementation. Am. J. Clin. Nutr.
85: 293S-299S
[Abstract][Full Text]
Benyo, Z., Gille, A., Bennett, C. L., Clausen, B. E., Offermanns, S.
(2006). Nicotinic Acid-Induced Flushing Is Mediated by Activation of Epidermal Langerhans Cells. Mol. Pharmacol.
70: 1844-1849
[Abstract][Full Text]
Gould, K. L.
(2006). Physiological severity of coronary artery stenosis. Am. J. Physiol. Heart Circ. Physiol.
291: H2583-H2585
[Full Text]
